AKBA logo

AKBA
Akebia Therapeutics Inc.

20,809
Mkt Cap
$370.19M
Volume
2.58M
52W High
$4.08
52W Low
$1.14
PE Ratio
-77.78
AKBA Fundamentals
Price
$1.40
Prev Close
$1.38
Open
$1.40
50D MA
$1.37
Beta
1.25
Avg. Volume
2.25M
EPS (Annual)
-$0.0208
P/B
11.40
Rev/Employee
$1.22M
$443.78
Loading...
Loading...
News
all
press releases
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +64.71% and +29.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Zacks·4d ago
News Placeholder
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Zacks·4d ago
News Placeholder
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below 200-Day Moving Average - Should You Sell...
MarketBeat·9d ago
News Placeholder
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat.com...
MarketBeat·17d ago
News Placeholder
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Akebia Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday...
MarketBeat·23d ago
News Placeholder
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)
BTIG Research reiterated a "buy" rating and issued a $4.00 target price on shares of Akebia Therapeutics in a research note on Tuesday...
MarketBeat·25d ago
News Placeholder
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets
Akebia Therapeutics (NASDAQ:AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs...
MarketBeat·30d ago
News Placeholder
Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock?
Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·1mo ago
<
1
2
...
>

Latest AKBA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.